Immix Biopharma (IMMX) Total Current Liabilities (2020 - 2026)

Immix Biopharma has reported Total Current Liabilities for 7 years, with the latest figure at $10.5 million in Q1 2026.

• Quarterly Total Current Liabilities rose 13.24% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 13.24% YoY) and the FY2025 annual result came in at $10.1 million, up 16.39% from the prior year.
• Total Current Liabilities improved to $10.5 million in Q1 2026 per IMMX's latest filing, from $10.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $10.9 million in Q3 2025 and troughed at $365086.0 in Q1 2022.
• A 5-year average of $5.3 million and a median of $3.9 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 530.22% in 2022, then increased 13.24% in 2026.
• Over 5 years, Total Current Liabilities stood at $1.3 million in 2022, then surged by 192.3% to $3.7 million in 2023, then surged by 133.41% to $8.7 million in 2024, then grew by 16.39% to $10.1 million in 2025, then increased by 4.24% to $10.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $10.5 million, $10.1 million, and $10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.